| 參考文獻 |
1
|
Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. Journal of the American Medical Association. 2006;295:65-73.
|
2
|
Collier J, Sherman M. Screening for hepatocellular carcinoma. Hepatology. 1998;27:273-8.
|
3
|
Ghany MG, Strader DB, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C: An update. Hepatology. 2009;49:1335-74.
|
4
|
Lim SG, Mohammed R, Yuen MF, et al. Prevention of hepatocellular carcinoma in hepatitis B virus infection. Journal of Gastroenterolology and Hepatology. 2009;24:1352-7.
|
5
|
Sherman M. Hepatocellular carcinoma: epidemiology, risk factors, and screening. Seminars in Liver Disease. 2005;25:143-54.
|
6
|
Sherman M. Screening for hepatocellular carcinoma. Best Practice & Research Clinical: Gastroenterology. 2005;19:101-18.
|
7
|
Tine F, Liberati A, Craxi A, et al. Interferon treatment in patients with chronic hepatitis B: a meta-analysis of the published literature. Journal of Hepatology. 1993;18:154-62.
|
8
|
Trevisani F, D’Intino PE, Morselli-Labate AM, et al. Serum α-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. Journal of Hepatology. 2001;34:570-5.
|
9
|
Ueno Y, Sollano JD, Garrell GC, et al. Prevention of hepatocellular carcinoma complicating chronic hepatitis C. Journal of Gastroenterology and Hepatology. 2009;24:531-6.
|
10
|
Wong DK, Cheung AM, O’Rourke K, et al. Effect of alpha-interferon treatment in patients with hepatitis B entigen-positive chronic hepatitis B. A meta-analysis. Annals of Internal Medicine( Practice Guidelines). 1993;119:312-23.
|
11
|
Wong DK, Cheung AM, O’Rourke K, et al. Effect of alpha-interferon treatment in patients with hepatitis B entigen-positive chronic hepatitis B. A meta-analysis. Annals of Internal Medicine( Practice Guidelines). 1993;119:312-23.
|
12
|
衛生福利部國民健康署 (2003)。整合性篩檢服務工作指引【期末報告】。
|